KX2-391
KX2-391 Basic information
- Product Name:
- KX2-391
- Synonyms:
-
- KX 01
- 5-[4-[2-(4-Morpholinyl)ethoxy]phenyl]-N-(phenylmethyl)-2-pyridineacetamide
- N-benzyl-2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)acetamide
- CS-234
- KX2-391;KX2 391;KX2391
- KX2-391 (KX01)
- Tirbanibulin, KX2-391
- Tirbanibulin
- CAS:
- 897016-82-9
- MF:
- C26H29N3O3
- MW:
- 431.53
- EINECS:
- 200-258-5
- Product Categories:
-
- Inhibitors
- Mol File:
- 897016-82-9.mol
KX2-391 Chemical Properties
- Boiling point:
- 680.9±55.0 °C(Predicted)
- Density
- 1.169
- storage temp.
- Store at -20°C
- solubility
- insoluble in H2O; ≥121 mg/mL in DMSO; ≥2.44 mg/mL in EtOH with gentle warming and ultrasonic
- form
- Powder
- pka
- 14.73±0.46(Predicted)
- color
- White to off-white
KX2-391 Usage And Synthesis
Uses
A synthetic, orally bioavailable small molecule and non-ATP competitive Src tyrosine kinase inhibitor with an IC50 of average 72 nM.
Uses
KX2-391 is a Src Inhibitor with efficacy against certain hepatic and leukemia cell lines.
Biological Activity
kx2-391 is a highly selective inhibitor of src kinase with ic50 value of 20nm [1].kx2-391 is a non-atp competitive inhibitor of src. it is the first inhibitor that targets src kinase within the substrate binding site. kx2-391 inhibits src catalyzed trans-phosphorylation of fak, shc, paxillin as well as src kinase autophosphorylation. kx2-391 has no effects on pdgfr, egfr, jak1, jak2 and lck demonstrating it as a selective inhibitor. it is also found to be an inhibitor of tubulin polymerization through binding to the unique confirmation on heterodimeric tubulin. in cellular assays, kx2-391 shows growth inhibition in nih3t3/c-src527f cells and syf/c-src527f cells with gi50 values of 23nm and 39nm, respectively [1, 2].since src acts as a regulator in cell proliferation survival, motility and invasiveness, kx2-391 is potent against a variety of solid tumors and many leukemia tumors. it is shown to inhibit primary tumor growth and to suppress metastasis [2].
target
Src (HuH7)
References
[1] fallah-tafti a, foroumadi a, tiwari r, et al. thiazolyl n-benzyl-substituted acetamide derivatives: synthesis, src kinase inhibitory and anticancer activities. european journal of medicinal chemistry, 2011, 46(10): 4853-4858.
[2] naing a, cohen r, dy g k, et al. a phase i trial of kx2-391, a novel non-atp competitive substrate-pocket-directed src inhibitor, in patients with advanced malignancies. investigational new drugs, 2013, 31(4): 967-973.
KX2-391Supplier
- Tel
- 023-88654579 13637703915
- 375097861@qq.com
- Tel
- sales@boylechem.com
- Tel
- +86 (531) 88811783
- sales@trio-pharmatech.com (International market)
- Tel
- 4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988
- Tel
- 400-400-6206333 18521732826
- market@aladdin-e.com